Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Rod Porter"'
Autor:
Masashi Yanagisawa, Christopher J. Winrow, Neil Upton, Gregor Sutcliffe, Jerome M Siegel, Takeshi Sakurai, John Renger, Rod Porter, Terrence P. McDonald, Jyrki P. Kukkonen, Thomas Kilduff, Laura Jacobson, Daniel Hoyer, Debbie Hartman, Luis De Lecea, Paul Coleman, Pascal Bonaventure, Gary Aston-Jones
Publikováno v:
IUPHAR/BPS Guide to Pharmacology CITE. 2023
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [43]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4494e816ff2e1ff073075e99b23a0035
https://doi.org/10.2218/gtopdb/f51/2023.1
https://doi.org/10.2218/gtopdb/f51/2023.1
Autor:
Heledd H. Jarosz-Griffiths, Ana I. Rojo, Iain A. Watson, Nigel M. Hooper, Mikhail V. Semenov, Weiming Xia, Simon Lovestone, Antonio Cuadrado, Anshua Ghosh, Raya Al-Shawi, Michael K. Harte, Joshua Jackson, Richard Killick, Christina Elliott, Paul Simons, George S. Baillie, Rod Porter, Peter J. Morin, Elena M. Ribe, Deepak Srivastava, Jane E. Preston, Katherine J. Sellers
Publikováno v:
Sellers, K J, Elliott, C, Jackson, J, Ghosh, A, Ribe, E, Rojo, A I, Jarosz-Griffiths, H H, Watson, I A, Xia, W, Semenov, M, Morin, P, Hooper, N M, Porter, R, Preston, J, Al-Shawi, R, Baillie, G, Lovestone, S, Cuadrado, A, Harte, M, Simons, P, Srivastava, D P & Killick, R 2017, ' Amyloid β synaptotoxicity is Wnt-PCP dependent and blocked by fasudil ', Alzheimer's & dementia : the journal of the Alzheimer's Association, vol. 14, no. 3, pp. 306-317 . https://doi.org/10.1016/j.jalz.2017.09.008
Alzheimer's & Dementia
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Alzheimer's & Dementia
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Introduction Synapse loss is the structural correlate of the cognitive decline indicative of dementia. In the brains of Alzheimer's disease sufferers, amyloid β (Aβ) peptides aggregate to form senile plaques but as soluble peptides are toxic to syn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79577d160acf38143e943e4b6020c9c8
https://eprints.whiterose.ac.uk/134114/1/1-s2.0-S1552526017337627-main.pdf
https://eprints.whiterose.ac.uk/134114/1/1-s2.0-S1552526017337627-main.pdf
Autor:
Antony W. Oliver, Dan Niculescu-Duvaz, Melanie Jayne Bayford, Elisenda Vendrell, Christopher J. Lord, Alan Ashworth, Ashley Jarvis, Rebekah Elisabeth Key, Laurence H. Pearl, Stuart Firth-Clark, Malini Menon, Richard Elliott, Mohan B. Rajasekaran, Raymond John Boffey, Filipa Lopes, Leandra Bowers, Rehan Aqil, Ines Trindade, Caroline J. Springer, Stewart B. Kirton, Trevor Perrior, Felix Munkonge, Rod Porter, Laura Fish, Robert McLeary
Publikováno v:
MedChemComm. 6:1687-1692
The tankyrase proteins (TNKS, TNKS2), members of the PARP superfamily of enzymes, are attractive anti-cancer drug targets, particularly as inhibition of their catalytic activity has been shown to antagonise oncogenic WNT signalling. To identify chemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f155625d77e675a849d9a2872fc97738
https://doi.org/10.1039/c5md00210a
https://doi.org/10.1039/c5md00210a
Autor:
Harrison D; NodThera Ltd., Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL, Essex, U.K., Billinton A; NodThera Ltd., Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL, Essex, U.K., Bock MG; NodThera Inc., P.O. Box 156, Suite 1702, 265 Franklin Street, Boston, Massachusetts 02110, United States., Doedens JR; NodThera Inc., 454 N 34th Street, Seattle, Washington 98103, United States., Gabel CA; NodThera Inc., 454 N 34th Street, Seattle, Washington 98103, United States., Holloway MK; Gfree Bio LLC, 5824 Brittlyns Ct, Austin, Texas 78730, United States., Porter RA; Rod Porter Consultancy, 89 Back Street, Ashwell, Baldock SG7 5PG, Hertfordshire, U.K., Reader V; NodThera Ltd., Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL, Essex, U.K., Scanlon J; NodThera Ltd., Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL, Essex, U.K., Schooley K; NodThera Inc., 454 N 34th Street, Seattle, Washington 98103, United States., Watt AP; NodThera Ltd., Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL, Essex, U.K.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2023 Nov 09; Vol. 66 (21), pp. 14897-14911. Date of Electronic Publication: 2023 Oct 24.
Autor:
Zirimwabagabo JO; Department of Chemistry, University of Sheffield, Sheffield S10 2TN, U.K., Jailani ABA; Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2TN, U.K., Avgoustou P; Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2TN, U.K., Tozer MJ; Matt Tozer Consultancy, Bognor Regis PO21 1DY, U.K., Gibson KR; Sandexis Medicinal Chemistry Ltd., Sandwich, Kent CT13 9ND, U.K., Glossop PA; Sandexis Medicinal Chemistry Ltd., Sandwich, Kent CT13 9ND, U.K., Mills JEJ; Sandexis Medicinal Chemistry Ltd., Sandwich, Kent CT13 9ND, U.K., Porter RA; Rod Porter Consultancy, Ashwell, Hertfordshire SG7 5PG, U.K., Blaney P; Concept Life Sciences, High Peak SK23 0PG, U.K., Wang N; Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2TN, U.K., Skerry TM; Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2TN, U.K., Richards GO; Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2TN, U.K., Harrity JPA; Department of Chemistry, University of Sheffield, Sheffield S10 2TN, U.K.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2021 Mar 25; Vol. 64 (6), pp. 3299-3319. Date of Electronic Publication: 2021 Mar 05.
Autor:
Harrison D; NodThera Ltd., Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden, Essex CB10 1XL, United Kingdom. Electronic address: david.harrison@nodthera.com., Boutard N; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Brzozka K; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Bugaj M; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Chmielewski S; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Cierpich A; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Doedens JR; NodThera Inc., 454 N 34(th) Street, Seattle, WA 98103, USA., Fabritius CRY; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Gabel CA; NodThera Inc., 454 N 34(th) Street, Seattle, WA 98103, USA., Galezowski M; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Kowalczyk P; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Levenets O; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Mroczkowska M; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Palica K; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Porter RA; Rod Porter Consultancy, 89 Back Street, Ashwell, Baldock, Hertfordshire SG7 5PG, United Kingdom., Schultz D; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Sowinska M; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Topolnicki G; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Urbanski P; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Woyciechowski J; Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland., Watt AP; NodThera Ltd., Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden, Essex CB10 1XL, United Kingdom.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2020 Dec 01; Vol. 30 (23), pp. 127560. Date of Electronic Publication: 2020 Sep 18.
Autor:
Avgoustou P; Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2TN, U.K., Jailani ABA; Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2TN, U.K., Zirimwabagabo JO; Department of Chemistry, University of Sheffield, Sheffield, S10 2TN, U.K., Tozer MJ; Matt Tozer Consultancy, Bognor Regis, PO21 1DY, U.K., Gibson KR; Sandexis Medicinal Chemistry Ltd, Sandwich, Kent CT13 9ND, U.K., Glossop PA; Sandexis Medicinal Chemistry Ltd, Sandwich, Kent CT13 9ND, U.K., Mills JEJ; Sandexis Medicinal Chemistry Ltd, Sandwich, Kent CT13 9ND, U.K., Porter RA; Rod Porter Consultancy, Ashwell, Hertfordshire SG7 5PG, U.K., Blaney P; Concept Life Sciences, High Peak, SK23 0PG, U.K., Bungay PJ; Sympetrus Ltd., Bishop's Stortford, Hertfordshire CM23 3BT, U.K., Wang N; Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2TN, U.K., Shaw AP; Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2TN, U.K., Bigos KJA; Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2TN, U.K., Holmes JL; Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2TN, U.K., Warrington JI; Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2TN, U.K., Skerry TM; Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2TN, U.K., Harrity JPA; Department of Chemistry, University of Sheffield, Sheffield, S10 2TN, U.K., Richards GO; Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2TN, U.K.
Publikováno v:
ACS pharmacology & translational science [ACS Pharmacol Transl Sci] 2020 Jun 25; Vol. 3 (4), pp. 706-719. Date of Electronic Publication: 2020 Jun 25 (Print Publication: 2020).
Autor:
Sellers KJ; King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK., Elliott C; King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK., Jackson J; The University of Manchester, Faculty of Biology, Medicine and Health, Division of Pharmacy and Optometry, Manchester, UK., Ghosh A; King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK., Ribe E; University of Oxford, Department of Psychiatry, Warneford Hospital, Oxford, UK., Rojo AI; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED). Instituto de Investigación Sanitaria La Paz (IdiPaz), Autonomous University of Madrid, Madrid, Spain., Jarosz-Griffiths HH; The University of Manchester, Faculty of Biology, Medicine and Health, Division of Neuroscience and Experimental Psychology, Manchester, UK., Watson IA; King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK., Xia W; Boston University School of Medicine, New England Geriatric Research Education and Clinical Center, Boston, USA., Semenov M; Boston University School of Medicine, New England Geriatric Research Education and Clinical Center, Boston, USA., Morin P; Boston University School of Medicine, New England Geriatric Research Education and Clinical Center, Boston, USA., Hooper NM; The University of Manchester, Faculty of Biology, Medicine and Health, Division of Neuroscience and Experimental Psychology, Manchester, UK., Porter R; Rod Porter, Rod Porter Consultancy, Baldock, England, UK., Preston J; King's College London, Institute of Pharmaceutical Science, Franklin-Wilkins Building, London, UK., Al-Shawi R; University College London, Centre for Amyloidosis and Acute Phase Proteins, Royal Free Campus, London, UK., Baillie G; University of Glasgow, Institute of Cardiovascular and Medical Science, Glasgow, Scotland., Lovestone S; University of Oxford, Department of Psychiatry, Warneford Hospital, Oxford, UK., Cuadrado A; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED). Instituto de Investigación Sanitaria La Paz (IdiPaz), Autonomous University of Madrid, Madrid, Spain., Harte M; The University of Manchester, Faculty of Biology, Medicine and Health, Division of Pharmacy and Optometry, Manchester, UK., Simons P; University College London, Centre for Amyloidosis and Acute Phase Proteins, Royal Free Campus, London, UK., Srivastava DP; King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK. Electronic address: Deepak.Srivastava@kcl.ac.uk., Killick R; King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK. Electronic address: Richard.1.Killick@kcl.ac.uk.
Publikováno v:
Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2018 Mar; Vol. 14 (3), pp. 306-317. Date of Electronic Publication: 2017 Oct 19.